CLAZAKIZUMAB (CLZ, ANTI-IL-6) AND TOCILIZUMAB (TCZ, ANTI-IL-6 RECEPTOR) DIFFERENTIALLY AFFECT IL-6/IL-6R SIGNALING BY MODULATING SOLUBLE IL-6R & GP130 IN PATIENTS TREATED FOR CHRONIC ANTIBODY-MEDIATED REJECTION (CABMR)

被引：0
|
作者：
Shin, Bongha [1 ]
Vo, Ashley [1 ]
Ge, Shili [1 ]
Petrosyan, Anna [1 ]
Ammerman, Noriko [1 ]
Jordan, Stanley [1 ]
Toyoda, Mieko [1 ]
机构：
[1] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
来源：
TRANSPLANT INTERNATIONAL | 2019年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
LBP023
引用
收藏
页码：410 / 410
页数：1
相关论文
共 50 条
  • [31] BLOCKING INTERLEUKIN-6 (IL-6) BY AN ANTI-INTERLEUKIN-6 RECEPTOR (IL-6R) MONOCLONAL ANTIBODY IN RHEUMATOID ARTHRITIS (RA)
    Choy, E. H. S.
    Isenberg, D. A.
    Garrood, T.
    Farrow, S.
    Ioannou, Y.
    Bird, H.
    Cheung, N.
    Williams, B. D.
    Hazleman, B.
    Price, R.
    Kishimoto, T.
    Panayi, G. S.
    RHEUMATOLOGY, 2002, 41 : 15 - 15
  • [32] Extended Experience Using Tocilizumab (Anti-IL6R, TCZ) for the Treatment of Chronic Antibody Mediated Rejection (CABMR).
    Choi, J.
    Aubert, O.
    Louie, S.
    Ammerman, N.
    Vo, A.
    Peng, A.
    Huang, E.
    Najjar, R.
    Puliyanda, D.
    Sethi, S.
    Haas, M.
    Lim, K.
    Loupy, A.
    Jordan, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 326 - 327
  • [33] Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease
    Nishimoto, Norihiro
    Terao, Kimio
    Mima, Toru
    Nakahara, Hideko
    Takagi, Nobuhiro
    Kakehi, Takahiro
    BLOOD, 2008, 112 (10) : 3959 - 3964
  • [34] A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection
    Doberer, Konstantin
    Duerr, Michael
    Halloran, Philip F.
    Eskandary, Farsad
    Budde, Klemens
    Regele, Heinz
    Reeve, Jeff
    Borski, Anita
    Kozakowski, Nicolas
    Reindl-Schwaighofer, Roman
    Waiser, Johannes
    Lachmann, Nils
    Schranz, Sabine
    Firbas, Christa
    Muehlbacher, Jakob
    Gelbenegger, Georg
    Perkmann, Thomas
    Wahrmann, Markus
    Kainz, Alexander
    Ristl, Robin
    Halleck, Fabian
    Bond, Gregor
    Chong, Edward
    Jilma, Bernd
    Boehmig, Georg A.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (03): : 708 - 722
  • [35] Role of interleukin-6 (IL-6) in platelet production: extension of a quantitative systems pharmacology model (QSPM) to describe anti-IL-6 and anti-IL-6 receptor therapies
    Koride, Sarita
    Nayak, Satyaprakash
    Banfield, Christopher
    Peterson, Mark C.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 : S102 - S102
  • [36] Monitoring Inflammatory Cytokine Levels in Kidney Transplant Patients (KTx Pts) with Chronic Antibody Mediated Rejection (cABMR) Treated with Clazakizumab (CLZ, Humanized Anti-IL-6 Monoclonal Antibody).
    Ge, S.
    Petrosyan, A.
    Chu, M.
    Ammerman, N.
    Vo, A.
    Jordan, S. C.
    Zhang, X.
    Toyoda, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 661 - 661
  • [37] Generation of 'truncated' interleukin-6 receptor (IL-6R) mRNA by alternative splicing;: a possible source of soluble IL-6R
    Holub, MC
    Szalai, C
    Polgár, A
    Tóth, S
    Falus, A
    IMMUNOLOGY LETTERS, 1999, 68 (01) : 121 - 124
  • [38] IL-6/IL-6R as a potential key signaling pathway in prostate cancer development
    Azevedo, Andreia
    Cunha, Virginia
    Teixeira, Ana Luisa
    Medeiros, Rui
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2011, 2 (12): : 384 - 396
  • [39] Postnatal expression of interleukin-6 (IL-6) and IL-6 receptor (IL-6R) mRNAs in rat sympathetic and sensory ganglia
    Gadient, RA
    Otten, U
    BRAIN RESEARCH, 1996, 724 (01) : 41 - 46
  • [40] Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer
    Heo, Tae-Hwe
    Wahler, Joseph
    Suh, Nanjoo
    ONCOTARGET, 2016, 7 (13) : 15460 - 15473
12345